Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM

0.00

Cullinan Therapeutics (NASDAQ: CGEM) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.87) by 13.79 percent. This is a 1.35 percent decrease over losses of $(0.74) per share from the same period last year.